Osteoarthritis Therapeutics Market Size To Reach $10.89 Billion By 2033

Osteoarthritis Therapeutics Market Growth & Trends 

The global osteoarthritis therapeutics market size is expected to reach USD 10.89 billion by 2033, registering a CAGR of 9.0% from 2025 to 2033, according to a new report by Grand View Research, Inc. The osteoarthritis therapeutics market is on the rise, driven by an increase in OA cases, especially among the aging population. In the U.S. alone, there are over 32.5 million OA patients, highlighting the demand for effective treatments. Ongoing research and development efforts are focused on creating new therapies, with a particular emphasis on understanding the disease and developing solutions to address its challenges.

Managing OA proves difficult owing to its dense tissue structure, but the introduction of novel drugs such as intra-articular drug administration has accelerated the development of targeted drug delivery. Researchers are actively exploring disease-modifying drugs and bioadaptive carriers to enhance the development of innovative osteoarthritis treatments. Market players are taking initiatives to contribute to market expansion, as seen with OrthoTrophix, Inc. presenting clinical data and a registration plan for TPX-100 for knee osteoarthritis at BIO 2022.

In addition, significant efforts are being made by key pharmaceutical companies and research institutes in realm of research and development, especially for disease-modifying osteoarthritis drugs. For instance, BioSenic's Phase 3 data presentation at the 2024 OARSI World Congress showcased the efficacy of JTA-004 in treating severe inflammatory knee osteoarthritis. The post hoc analysis concluded that JTA-004 is both safe and effective, offering targeted pain management for this specific subtype of condition. These advancements in targeted drug delivery and disease-modifying drugs, as demonstrated by presentations and positive trial results, are contributing to the expansion of the market for novel osteoarthritis treatments.

Moreover, the market for OA is experiencing significant growth owing to the introduction of personalized medications such as Bisphosphonates (anti-resorptive drugs) and Synvisc-ONE injection. In addition, pharmaceutical companies and research institutions are actively engaged in developing personalized treatments and cell-based therapies for OA. In December 2023, researchers at Columbia University made a breakthrough discovery of stem cells in adult mice capable of maintaining healthy cartilage in joints, with their decline contributing to OA development due to aging and injury.

Investing in this sector offers companies the opportunity to capitalize on evolving demands, thus gaining a competitive advantage. By leading innovative medication development, companies establish themselves as frontrunners, solidifying their position in the market. The advent of personalized OA medications and advancements in cell-based therapies are key drivers of market expansion, empowering companies to emerge as leaders in the field.

 Request a free sample copy or view report summary: Osteoarthritis Therapeutics Market Report

Osteoarthritis Therapeutics Market Report Highlights

• Viscosupplementats segment dominated the market with the largest revenue share of 48.85% in 2024, led by hyaluronic acid (HA) injections, has become a significant treatment option for knee osteoarthritis (OA).

• The knee osteoarthritis (OA) segment dominated the market with the largest revenue share of 59.82% in 2024, driven by the high prevalence of the condition and increasing global incidence.

• The orthopedic surgeons segment dominated the market with the largest revenue share of 37.67% in 2024, driven by the increasing adoption of innovative cartilage restoration technologies like the Agili-C implant.

• The North American osteoarthritis therapeutics market dominated the global market with a share of 35.05% in 2024 and is experiencing substantial growth, driven by the high prevalence of osteoarthritis, particularly among the aging population.

Osteoarthritis Therapeutics Market Segmentation

Grand View Research has segmented the global osteoarthritis therapeutics market on the basis of on product, application, primary user, and region:

Osteoarthritis Therapeutics Product Outlook (Revenue, USD Million, 2021 - 2033)

• Viscosupplements

• Platelet-Rich Plasma (PRP) Therapy

• Bone Graft Substitutes

• BMAC (Bone Marrow Aspirate Concentrate) Therapy

• Adipose Tissue Therapy

• Autologous Chondrocyte Implantation (ACI), Including MACI

• Stem Cell (other)

• Other (Cartilage Resurfacing Products)

Osteoarthritis Therapeutics Application Outlook (Revenue, USD Million, 2021 - 2033)

• Knee Osteoarthritis

• Hip Osteoarthritis

• Shoulder Osteoarthritis

• Spine Osteoarthritis

• Ankle & Foot Osteoarthritis

• Other

Osteoarthritis Therapeutics Primary User Outlook (Revenue, USD Million, 2021 - 2033)

• Orthopedic Surgeons

• Rheumatologists

• Sports Medicine Specialists

• Regenerative Medicine Specialists

• Other

Osteoarthritis Therapeutics Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Osteoarthritis Therapeutics Market

• Stryker

• Zimmer Biomet Holdings, Inc.

• Medtronic

• Anika Therapeutics, Inc.

• Bioventus

• Vericel Corporation

• Smith & Nephew

• Fidia Farmaceutici S.p.A.

• SEIKAGAKU CORPORATION

• Sanofi